-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Iterum Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2017 to Q3 2024.
- Iterum Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$6.09M, a 57.2% decline year-over-year.
- Iterum Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$30.6M, a 1.75% increase year-over-year.
- Iterum Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2023 was -$38.4M, a 13.6% increase from 2022.
- Iterum Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$44.4M, a 51.5% increase from 2021.
- Iterum Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$91.6M, a 76.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)